Supernus Pharmaceuticals Q3 2024 GAAP EPS $0.69 Beats $0.02 Estimate, Sales $175.689M Beat $157.298M Estimate
Supernus Pharmaceuticals Q3 2024 GAAP EPS $0.69 Beats $0.02 Estimate, Sales $175.689M Beat $157.298M Estimate
supernus pharmaceuticals 2024年第三季度的普通会计准则每股收益为0.69美元，超过0.02美元的预期，销售额为17568.9万美元，超过15729.8万美元的预期
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.02 by 3350 percent. The company reported quarterly sales of $175.689 million which beat the analyst consensus estimate of $157.298 million by 11.69 percent. This is a 14.17 percent increase over sales of $153.880 million the same period last year.
supernus pharmaceuticals（纳斯达克:SUPN）报告每股盈利为0.69美元，比分析师共识估计的0.02美元增长了3350％。该公司报告的季度销售额为17568.9万美元，比分析师共识估计的15729.8万美元高出11.69％。这是去年同期的销售额15388万美元的14.17％增长。
热门讨论
中概股财报季火热：惊喜盈利能否延续涨势？
1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？
Moomoo News Global
03/04 23:26
中国两会：会议前后股票价格走势的主要要点